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A short title: Sialadenitis in HAM post LDLT 
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Introduction 
Both hepatitis C virus (HCV) and human T-cell virus type I (HTLV-I) have been 
reported to be associated with the onset of Sjögren’s syndrome (SS) (1, 2). Since 
HCV infection demonstrates exocrine dysfunction along with sialadenitis, the 
American-European Consensus Group for SS excluded HCV infection in 
diagnosis of SS (3). We have previously reported that an epidemiologic study 
showed a high prevalence of SS in anti-HTLV-I antibody positive subjects (4). In 
this case, a complication of HAM after living-donor liver transplantation (LDLT) 
has recently been reported (5). Here, we additionally report the emergence of 
unusual sialadenitis in this patient. 
 
Case report 
The complication of HAM in this patient was already reported by Soyama et 
al.(5). Briefly, LDLT was performed for the patient who had suffered from 
decompensated liver cirrhosis due to HCV infection in August 2002. Both the 
patient and his younger sister as a donor were seropositive for anti-HTLV-I 
antibody. Immediately after LDLT in October 2002, interferon (IFN) -2b with 
ribavirin were administered after recurrence of the HCV infection was confirmed, 
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but HAM appeared 18 months after LDLT. Though pegylated IFN -2b with 
ribavirin were administered for 48 weeks against the HCV infection, no response 
was observed with the recurrence of active hepatitis.  
When the patient was admitted to the Department of Gastroenterology 
for determination of the therapeutic strategy in September 2008, xerostomia was 
newly detected. The clinical manifestations of HAM, including spastic gait and 
bladder symptoms, since the last diagnosis of HAM was confirmed. Elevation of 
aspartate aminotransferase (53 IU/l), alanine aminotransferase (47 IU/l), and IgG 
(2630 mg/dl) were observed with normal total bilirubin（0.7 mg/dl）. Type IV 
collagen and quantitative HCV ribonucleoprotein were elevated to 290 ng/ml 
(normal; ≤140) and 7.1 log IU/ml (normal; undetected) with reduced total branch 
chain amino acids (285 mol/l; normal: 379-688). A liver biopsy, which had 
resulted in a hospital admission in September 2008, showed chronic hepatitis 
with fibrous enlargement of the portal area, inflammatory cell infiltration, and 
piecemeal necrosis. The relative copy number of HTLV-I against -globin in 
peripheral blood sample was 2.56 x 102/104 cells by real-time polymerase chain 
reaction. Along with xerostomia, both the Saxon test (1.1 g/2 minutes; <2g: 
positive) and Schirmer test (3mm/5 minutes; <5mm: positive) were positive with 
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negative results for anti-SS-A/SS-B antibodies and sialography. However, minor 
salivary gland biopsy (Fig. 1A) demonstrated more than 60 counts of 
mononuclear cells infiltration, which were confirmed as dominant infiltration of 
macrophages. Although the patient showed signs of xerostomia, positive exocrine 
dysfunction, and mononuclear cell infiltration into the minor salivary gland 
(MSG), SS was excluded according to the criteria determined by the 
American-European Consensus Group (3). Immunohistochemistry using 
monoclonal antibodies for MSG demonstrated positive staining of CD68 on the 
infiltrating mononuclear cells (Fig. 1B). Compared to the prevalence of CD68, 
the prevalence of CD4 (Fig. 1C) or CD8 (Fig. 1D) was less than that of CD68, 
macrophage. Major histocompatibility (MHC) class II was found in humal tonsil 
as a positive control (Fig. 1E) and MNCs in the MSG of this patient (Fig. 1F). 




 HCV-related SS is reported to be characterized by a high prevalence of 
cryoglobulinemia with a low frequency of anti-SS-A/SS-B antibodies (6). In our 
                                                   Nakamura H et al  page         6
case, sialadenitis without SS-related autoantibodies is compatible with the 
characteristics of HCV-related SS. However, HCV infection usually shows 
infiltration of CD4+ T lymphocytes into the MSG, which is incompatible with the 
present macrophagic infiltration. Furthermore, it has previously been reported 
that IFNs have the potential to cause autoimmune diseases such as autoimmune 
thyroid diseases, systemic lupus erythematosus, rheumatoid arthritis, or SS (7, 8). 
Unoki et al reported that administration of IFN-alpha-2b for a patient with type C 
chronic active hepatitis induced SS with sicca symptoms and elevation of 
autoantibodies, suggesting IFN per se had a potential to form autoimmune 
disorders in patients with viral hepatitis (9). 
 With regard to HTLV-I infection, prognosis of HTLV-I-positive renal 
transplant recipients was previously reported (10), in which both living-related 
and cadaveric kidneys from HTLV-I carriers could be used for 
HTLV-I-seropositive recipients because low occurrence of adult-T cell leukemia 
was observed. HTLV-I is also one of the candidates for trigger of sialadenistis. 
We have previously reported a high prevalence of SS in patients with HAM (2). 
However, the phenotype of predominant mononuclear cells found in HAM-SS 
patients was CD4+ T lymphocytes, which was similar to the type of mononuclear 
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cells in HTLV-I-seronegative SS patients. Previously, Ishiguro et al (11) 
established a rat model of HTLV-I infection, in which massive foamy 
macrophages infiltrated the spinal cord and clinical manifestations of the rat 
resembled those of HAM patients. Meanwhile, our patient showed 
macrophage-dominant MNC infiltration into the MSG. Although the 
pathogenesis of the rat model might be different from that of human HAM 
because lymphocytic infiltration is an apparent characteristic of HAM patients, 
an unrecognized trigger might have induced infiltration of macrophages into the 
MSG in our patient. 
 Graft-versus-host-disease (GVHD) is considered to be a candidate cause 
of sialadenitis. Fujiwara et al (12) have previously reported sialadenitis in 
experimental GVHD in an animal model, in which the nonirradiated mice into 
which spleen cells were injected developed chronic GVHD. In their report, 
sialadenitis dominantly with CD4+ T lymphocytes was observed, although with a 
low frequency of macrophages, B cells, or plasma cells. However, chronic 
GVHD has rarely been reported after LDLT. Sun et al (13) reported a case of 
GVHD 4 months after cadaveric liver transplantation. In their report, the patient 
showed gastrointestinal symptoms, which was determined as T lymphocyte 
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infiltration by the colonic biopsy. 
 In summary, the mechanism by which sialadenitis is induced remains to 
be clarified. However, both active hepatitis and HAM might have the potential 
for viral-induced recruitment of mononuclear infiltration. Furthermore, double 
viral infection might provoke a strong eliminating reaction compared to single 
viral infection. Though an antiviral reaction is considered to be raised by innate 
immunity through toll-like receptors (14), intense antigen-presentation capacity 
might be yielded by induction of macrophages. 
 
All authors declare no conflicts of interest in this paper. 
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Figure legends 
 
Figure 1 Phenotypic markers expressed in the minor salivary gland (MSG). 
Immunohistochemistry was performed for formalin-fixed, paraffin-embedded 
sections (3 µm thick) from the MSG using the streptavidin-biotin method. 
Primary antibodies were used as follows; A:hematoxylin eosin staining, B: CD68, 
C: CD4, D: CD8, E: MHC class II staining in human tonsil (positive control), F: 
MHC class II staining of the MSG of the patient (Original magnification; A-D, F: 
x200, E: x100) Hematoxylin was used as a counterstain. 
